galactose inducible promoter gal1 10 Search Results


90
AstraZeneca ltd ar-m961
A, The percentage of cells bearing neurites from dissociated DRG cultures isolated from wild-type and galanin knock-out animals in the presence and absence of 100 nm <t>AR-M961</t> or AR-M1896 8 hr after plating. The addition of either AR-M961 or AR-M1896 rescued the deficits in percentages of cells producing neurites seen in galanin knock-out cultures to near wild-type levels. Addition of AR-M1896 to wild-type cultures significantly increased the percentage of cells bearing neurites compared with controls. Although addition of AR-M961 increased the percentage, this was not significant. B, The length of neurite outgrowth from dissociated DRG cultures isolated from wild-type animals in the presence and absence of 100 nm AR-M961 or AR-M1896 8 hr after plating. Addition of either AR-M961 or AR-M1896 significantly increased neurite length. C, The percentage of cells bearing neurites from dissociated DRG cultures isolated from wild-type and galanin knock-out animals in the presence and absence of 10 μm BIM or 10 μm BIM plus AR-M1896. Significant deficits are seen in the number of cells producing neurites in wild-type cultures in the presence of 10 μm BIM, which was not rescued by the addition of 100 nm AR-M1896. Addition of 10 μm BIM had no effect on mutant cultures. Data are presented as percentage of cells bearing neurites or mean ± SEM length (t test; *p < 0.05; ***p < 0.001; n= 5).
Ar M961, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/galactose+inducible+promoter+gal1+10/pmc06741899-67-58-73?v=AstraZeneca+ltd
Average 90 stars, based on 1 article reviews
ar-m961 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

92
R&D Systems polyclonal goat antihuman galectin 10 antibody
A, The percentage of cells bearing neurites from dissociated DRG cultures isolated from wild-type and galanin knock-out animals in the presence and absence of 100 nm <t>AR-M961</t> or AR-M1896 8 hr after plating. The addition of either AR-M961 or AR-M1896 rescued the deficits in percentages of cells producing neurites seen in galanin knock-out cultures to near wild-type levels. Addition of AR-M1896 to wild-type cultures significantly increased the percentage of cells bearing neurites compared with controls. Although addition of AR-M961 increased the percentage, this was not significant. B, The length of neurite outgrowth from dissociated DRG cultures isolated from wild-type animals in the presence and absence of 100 nm AR-M961 or AR-M1896 8 hr after plating. Addition of either AR-M961 or AR-M1896 significantly increased neurite length. C, The percentage of cells bearing neurites from dissociated DRG cultures isolated from wild-type and galanin knock-out animals in the presence and absence of 10 μm BIM or 10 μm BIM plus AR-M1896. Significant deficits are seen in the number of cells producing neurites in wild-type cultures in the presence of 10 μm BIM, which was not rescued by the addition of 100 nm AR-M1896. Addition of 10 μm BIM had no effect on mutant cultures. Data are presented as percentage of cells bearing neurites or mean ± SEM length (t test; *p < 0.05; ***p < 0.001; n= 5).
Polyclonal Goat Antihuman Galectin 10 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/galactose+inducible+promoter+gal1+10/pmc03361262-58-17-25?v=R%26D+Systems
Average 92 stars, based on 1 article reviews
polyclonal goat antihuman galectin 10 antibody - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier

90
PeproTech recombinant gal1
TAMs play a crucial role in the <t>Gal1‐induced</t> tumor progression. A) LGALS1 expression in normal tissues and tumor tissues of HCC patients based on TCGA database. B) Comparison of overall survival between Gal1 high expression and Gal1 low expression groups in TCGA cohort. C) Representative IHC staining of Gal1 in HCC tissue array (left) and comparison of relative Gal1 expression between normal tissues (n = 38) and tumor tissues (n = 62) according to immunohistochemical staining score (right). D) Comparison of Gal1 expression between patients with early stage (TNM stage I/ II, n = 38) and advanced stage (TNM stage III, n = 24). E) Kaplan‐Meier curve analysis of overall survival of HCC patients with high Gal1 expression (IHC staining score ≥ 6, n = 35) compared with patients with low Gal1 expression (IHC staining score < 6, n = 27). F) Western blot analysis of Gal1 protein expression in shNC and shGal1 hepa1‐6 cells. G) Images of HCC tumor (left) and tumor weight (right) in the orthotopic HCC mouse models (n = 6). H) Comparison of overall survival between shNC and shGal1 orthotopic tumor models (n = 6). I) The proliferation of shNC and shGal1 cells measured by CCK8 assay. J) Flow chart of shNC and shGal1 cell implantation and macrophage depletion. K) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC mouse models with or without macrophage depletion (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
Recombinant Gal1, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/galactose+inducible+promoter+gal1+10/pmc11923918-180-18-26?v=PeproTech
Average 90 stars, based on 1 article reviews
recombinant gal1 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

86
Galectin Therapeutics fitc labelled galectin 10 crystals
TAMs play a crucial role in the <t>Gal1‐induced</t> tumor progression. A) LGALS1 expression in normal tissues and tumor tissues of HCC patients based on TCGA database. B) Comparison of overall survival between Gal1 high expression and Gal1 low expression groups in TCGA cohort. C) Representative IHC staining of Gal1 in HCC tissue array (left) and comparison of relative Gal1 expression between normal tissues (n = 38) and tumor tissues (n = 62) according to immunohistochemical staining score (right). D) Comparison of Gal1 expression between patients with early stage (TNM stage I/ II, n = 38) and advanced stage (TNM stage III, n = 24). E) Kaplan‐Meier curve analysis of overall survival of HCC patients with high Gal1 expression (IHC staining score ≥ 6, n = 35) compared with patients with low Gal1 expression (IHC staining score < 6, n = 27). F) Western blot analysis of Gal1 protein expression in shNC and shGal1 hepa1‐6 cells. G) Images of HCC tumor (left) and tumor weight (right) in the orthotopic HCC mouse models (n = 6). H) Comparison of overall survival between shNC and shGal1 orthotopic tumor models (n = 6). I) The proliferation of shNC and shGal1 cells measured by CCK8 assay. J) Flow chart of shNC and shGal1 cell implantation and macrophage depletion. K) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC mouse models with or without macrophage depletion (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
Fitc Labelled Galectin 10 Crystals, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/galactose+inducible+promoter+gal1+10/med_rxiv__2025__11__26__25341000-452-54-55?v=Galectin+Therapeutics
Average 86 stars, based on 1 article reviews
fitc labelled galectin 10 crystals - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

93
Addgene inc 12urab
TAMs play a crucial role in the <t>Gal1‐induced</t> tumor progression. A) LGALS1 expression in normal tissues and tumor tissues of HCC patients based on TCGA database. B) Comparison of overall survival between Gal1 high expression and Gal1 low expression groups in TCGA cohort. C) Representative IHC staining of Gal1 in HCC tissue array (left) and comparison of relative Gal1 expression between normal tissues (n = 38) and tumor tissues (n = 62) according to immunohistochemical staining score (right). D) Comparison of Gal1 expression between patients with early stage (TNM stage I/ II, n = 38) and advanced stage (TNM stage III, n = 24). E) Kaplan‐Meier curve analysis of overall survival of HCC patients with high Gal1 expression (IHC staining score ≥ 6, n = 35) compared with patients with low Gal1 expression (IHC staining score < 6, n = 27). F) Western blot analysis of Gal1 protein expression in shNC and shGal1 hepa1‐6 cells. G) Images of HCC tumor (left) and tumor weight (right) in the orthotopic HCC mouse models (n = 6). H) Comparison of overall survival between shNC and shGal1 orthotopic tumor models (n = 6). I) The proliferation of shNC and shGal1 cells measured by CCK8 assay. J) Flow chart of shNC and shGal1 cell implantation and macrophage depletion. K) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC mouse models with or without macrophage depletion (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
12urab, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/galactose+inducible+promoter+gal1+10/pmc10853770-26-19-20?v=Addgene+inc
Average 93 stars, based on 1 article reviews
12urab - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

86
Addgene inc s cerevisiae
TAMs play a crucial role in the <t>Gal1‐induced</t> tumor progression. A) LGALS1 expression in normal tissues and tumor tissues of HCC patients based on TCGA database. B) Comparison of overall survival between Gal1 high expression and Gal1 low expression groups in TCGA cohort. C) Representative IHC staining of Gal1 in HCC tissue array (left) and comparison of relative Gal1 expression between normal tissues (n = 38) and tumor tissues (n = 62) according to immunohistochemical staining score (right). D) Comparison of Gal1 expression between patients with early stage (TNM stage I/ II, n = 38) and advanced stage (TNM stage III, n = 24). E) Kaplan‐Meier curve analysis of overall survival of HCC patients with high Gal1 expression (IHC staining score ≥ 6, n = 35) compared with patients with low Gal1 expression (IHC staining score < 6, n = 27). F) Western blot analysis of Gal1 protein expression in shNC and shGal1 hepa1‐6 cells. G) Images of HCC tumor (left) and tumor weight (right) in the orthotopic HCC mouse models (n = 6). H) Comparison of overall survival between shNC and shGal1 orthotopic tumor models (n = 6). I) The proliferation of shNC and shGal1 cells measured by CCK8 assay. J) Flow chart of shNC and shGal1 cell implantation and macrophage depletion. K) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC mouse models with or without macrophage depletion (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
S Cerevisiae, supplied by Addgene inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/galactose+inducible+promoter+gal1+10/pmc06097235__NIHMS970107___supplement___1-64-73-115?v=Addgene+inc
Average 86 stars, based on 1 article reviews
s cerevisiae - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

86
Thermo Fisher gene exp st6gal1 hs00949382 m1
TAMs play a crucial role in the <t>Gal1‐induced</t> tumor progression. A) LGALS1 expression in normal tissues and tumor tissues of HCC patients based on TCGA database. B) Comparison of overall survival between Gal1 high expression and Gal1 low expression groups in TCGA cohort. C) Representative IHC staining of Gal1 in HCC tissue array (left) and comparison of relative Gal1 expression between normal tissues (n = 38) and tumor tissues (n = 62) according to immunohistochemical staining score (right). D) Comparison of Gal1 expression between patients with early stage (TNM stage I/ II, n = 38) and advanced stage (TNM stage III, n = 24). E) Kaplan‐Meier curve analysis of overall survival of HCC patients with high Gal1 expression (IHC staining score ≥ 6, n = 35) compared with patients with low Gal1 expression (IHC staining score < 6, n = 27). F) Western blot analysis of Gal1 protein expression in shNC and shGal1 hepa1‐6 cells. G) Images of HCC tumor (left) and tumor weight (right) in the orthotopic HCC mouse models (n = 6). H) Comparison of overall survival between shNC and shGal1 orthotopic tumor models (n = 6). I) The proliferation of shNC and shGal1 cells measured by CCK8 assay. J) Flow chart of shNC and shGal1 cell implantation and macrophage depletion. K) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC mouse models with or without macrophage depletion (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
Gene Exp St6gal1 Hs00949382 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/galactose+inducible+promoter+gal1+10/10__1074_slash_jbc__ra120__014126-207-25-29?v=Thermo+Fisher
Average 86 stars, based on 1 article reviews
gene exp st6gal1 hs00949382 m1 - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

96
Vector Laboratories galactose inducible ptsg based vector
TAMs play a crucial role in the <t>Gal1‐induced</t> tumor progression. A) LGALS1 expression in normal tissues and tumor tissues of HCC patients based on TCGA database. B) Comparison of overall survival between Gal1 high expression and Gal1 low expression groups in TCGA cohort. C) Representative IHC staining of Gal1 in HCC tissue array (left) and comparison of relative Gal1 expression between normal tissues (n = 38) and tumor tissues (n = 62) according to immunohistochemical staining score (right). D) Comparison of Gal1 expression between patients with early stage (TNM stage I/ II, n = 38) and advanced stage (TNM stage III, n = 24). E) Kaplan‐Meier curve analysis of overall survival of HCC patients with high Gal1 expression (IHC staining score ≥ 6, n = 35) compared with patients with low Gal1 expression (IHC staining score < 6, n = 27). F) Western blot analysis of Gal1 protein expression in shNC and shGal1 hepa1‐6 cells. G) Images of HCC tumor (left) and tumor weight (right) in the orthotopic HCC mouse models (n = 6). H) Comparison of overall survival between shNC and shGal1 orthotopic tumor models (n = 6). I) The proliferation of shNC and shGal1 cells measured by CCK8 assay. J) Flow chart of shNC and shGal1 cell implantation and macrophage depletion. K) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC mouse models with or without macrophage depletion (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
Galactose Inducible Ptsg Based Vector, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/galactose+inducible+promoter+gal1+10/pmc12827457-263-8-10?v=Vector+Laboratories
Average 96 stars, based on 1 article reviews
galactose inducible ptsg based vector - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

90
GlycoTech Corporation sialyl lewis x polyacrylamide 01-045 antibody
TAMs play a crucial role in the <t>Gal1‐induced</t> tumor progression. A) LGALS1 expression in normal tissues and tumor tissues of HCC patients based on TCGA database. B) Comparison of overall survival between Gal1 high expression and Gal1 low expression groups in TCGA cohort. C) Representative IHC staining of Gal1 in HCC tissue array (left) and comparison of relative Gal1 expression between normal tissues (n = 38) and tumor tissues (n = 62) according to immunohistochemical staining score (right). D) Comparison of Gal1 expression between patients with early stage (TNM stage I/ II, n = 38) and advanced stage (TNM stage III, n = 24). E) Kaplan‐Meier curve analysis of overall survival of HCC patients with high Gal1 expression (IHC staining score ≥ 6, n = 35) compared with patients with low Gal1 expression (IHC staining score < 6, n = 27). F) Western blot analysis of Gal1 protein expression in shNC and shGal1 hepa1‐6 cells. G) Images of HCC tumor (left) and tumor weight (right) in the orthotopic HCC mouse models (n = 6). H) Comparison of overall survival between shNC and shGal1 orthotopic tumor models (n = 6). I) The proliferation of shNC and shGal1 cells measured by CCK8 assay. J) Flow chart of shNC and shGal1 cell implantation and macrophage depletion. K) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC mouse models with or without macrophage depletion (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
Sialyl Lewis X Polyacrylamide 01 045 Antibody, supplied by GlycoTech Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/galactose+inducible+promoter+gal1+10/us11597770-1903-30-34?v=GlycoTech+Corporation
Average 90 stars, based on 1 article reviews
sialyl lewis x polyacrylamide 01-045 antibody - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Oxford Glycosystems sle x -bsa
Kinetics and thermodynamics of binding of <t> sLe x </t> and Le x conjugates to scFvs
Sle X Bsa, supplied by Oxford Glycosystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/galactose+inducible+promoter+gal1+10/pmc00022023-99-14-17?v=Oxford+Glycosystems
Average 90 stars, based on 1 article reviews
sle x -bsa - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Enzo Biochem m86 anti-alpha-gal
Kinetics and thermodynamics of binding of <t> sLe x </t> and Le x conjugates to scFvs
M86 Anti Alpha Gal, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/galactose+inducible+promoter+gal1+10/pmc05434867-99-22-25?v=Enzo+Biochem
Average 90 stars, based on 1 article reviews
m86 anti-alpha-gal - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

86
Galectin Therapeutics charcot leyden crystal protein clcp
Kinetics and thermodynamics of binding of <t> sLe x </t> and Le x conjugates to scFvs
Charcot Leyden Crystal Protein Clcp, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/galactose+inducible+promoter+gal1+10/pm42121933-125-5-0?v=Galectin+Therapeutics
Average 86 stars, based on 1 article reviews
charcot leyden crystal protein clcp - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

Image Search Results


A, The percentage of cells bearing neurites from dissociated DRG cultures isolated from wild-type and galanin knock-out animals in the presence and absence of 100 nm AR-M961 or AR-M1896 8 hr after plating. The addition of either AR-M961 or AR-M1896 rescued the deficits in percentages of cells producing neurites seen in galanin knock-out cultures to near wild-type levels. Addition of AR-M1896 to wild-type cultures significantly increased the percentage of cells bearing neurites compared with controls. Although addition of AR-M961 increased the percentage, this was not significant. B, The length of neurite outgrowth from dissociated DRG cultures isolated from wild-type animals in the presence and absence of 100 nm AR-M961 or AR-M1896 8 hr after plating. Addition of either AR-M961 or AR-M1896 significantly increased neurite length. C, The percentage of cells bearing neurites from dissociated DRG cultures isolated from wild-type and galanin knock-out animals in the presence and absence of 10 μm BIM or 10 μm BIM plus AR-M1896. Significant deficits are seen in the number of cells producing neurites in wild-type cultures in the presence of 10 μm BIM, which was not rescued by the addition of 100 nm AR-M1896. Addition of 10 μm BIM had no effect on mutant cultures. Data are presented as percentage of cells bearing neurites or mean ± SEM length (t test; *p < 0.05; ***p < 0.001; n= 5).

Journal: The Journal of Neuroscience

Article Title: The Second Galanin Receptor GalR2 Plays a Key Role in Neurite Outgrowth from Adult Sensory Neurons

doi: 10.1523/JNEUROSCI.23-02-00416.2003

Figure Lengend Snippet: A, The percentage of cells bearing neurites from dissociated DRG cultures isolated from wild-type and galanin knock-out animals in the presence and absence of 100 nm AR-M961 or AR-M1896 8 hr after plating. The addition of either AR-M961 or AR-M1896 rescued the deficits in percentages of cells producing neurites seen in galanin knock-out cultures to near wild-type levels. Addition of AR-M1896 to wild-type cultures significantly increased the percentage of cells bearing neurites compared with controls. Although addition of AR-M961 increased the percentage, this was not significant. B, The length of neurite outgrowth from dissociated DRG cultures isolated from wild-type animals in the presence and absence of 100 nm AR-M961 or AR-M1896 8 hr after plating. Addition of either AR-M961 or AR-M1896 significantly increased neurite length. C, The percentage of cells bearing neurites from dissociated DRG cultures isolated from wild-type and galanin knock-out animals in the presence and absence of 10 μm BIM or 10 μm BIM plus AR-M1896. Significant deficits are seen in the number of cells producing neurites in wild-type cultures in the presence of 10 μm BIM, which was not rescued by the addition of 100 nm AR-M1896. Addition of 10 μm BIM had no effect on mutant cultures. Data are presented as percentage of cells bearing neurites or mean ± SEM length (t test; *p < 0.05; ***p < 0.001; n= 5).

Article Snippet: Treatments Cells were cultured in DMEM–F12-supplemented medium as described above with or without the addition of the following chemicals: 1 n m M35 [galanin(1–13)bradykinin(2–9)] (Bachem UK, Essex, UK), 100 n m galanin peptide (Bachem UK), 10 μ m bisindolylmaleimide I (BIM) (Calbiochem, La Jolla, CA), 10 n m RWJ-57408 [2,3-dihydro-2-(4-methyl-phenyl)-1,4-dithiepine-1,1,4,4-tetroxide] (Johnson & Johnson, Spring House, PA), and 100 n m AR-M961 ([Sar(1), d -Ala 12 ]Gal(1–16)-NH 2 ) or AR-M1896 [Gal(2–11)Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-NH 2 ] (AstraZeneca, Montreal, Quebec, Canada). . Data analysis Cultures were washed with PBS and fixed with 4% paraformaldehyde for 20 min at room temperature.

Techniques: Isolation, Knock-Out, Mutagenesis

TAMs play a crucial role in the Gal1‐induced tumor progression. A) LGALS1 expression in normal tissues and tumor tissues of HCC patients based on TCGA database. B) Comparison of overall survival between Gal1 high expression and Gal1 low expression groups in TCGA cohort. C) Representative IHC staining of Gal1 in HCC tissue array (left) and comparison of relative Gal1 expression between normal tissues (n = 38) and tumor tissues (n = 62) according to immunohistochemical staining score (right). D) Comparison of Gal1 expression between patients with early stage (TNM stage I/ II, n = 38) and advanced stage (TNM stage III, n = 24). E) Kaplan‐Meier curve analysis of overall survival of HCC patients with high Gal1 expression (IHC staining score ≥ 6, n = 35) compared with patients with low Gal1 expression (IHC staining score < 6, n = 27). F) Western blot analysis of Gal1 protein expression in shNC and shGal1 hepa1‐6 cells. G) Images of HCC tumor (left) and tumor weight (right) in the orthotopic HCC mouse models (n = 6). H) Comparison of overall survival between shNC and shGal1 orthotopic tumor models (n = 6). I) The proliferation of shNC and shGal1 cells measured by CCK8 assay. J) Flow chart of shNC and shGal1 cell implantation and macrophage depletion. K) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC mouse models with or without macrophage depletion (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Journal: Advanced Science

Article Title: Galectin‐1‐Induced Tumor Associated Macrophages Repress Antitumor Immunity in Hepatocellular Carcinoma Through Recruitment of Tregs

doi: 10.1002/advs.202408788

Figure Lengend Snippet: TAMs play a crucial role in the Gal1‐induced tumor progression. A) LGALS1 expression in normal tissues and tumor tissues of HCC patients based on TCGA database. B) Comparison of overall survival between Gal1 high expression and Gal1 low expression groups in TCGA cohort. C) Representative IHC staining of Gal1 in HCC tissue array (left) and comparison of relative Gal1 expression between normal tissues (n = 38) and tumor tissues (n = 62) according to immunohistochemical staining score (right). D) Comparison of Gal1 expression between patients with early stage (TNM stage I/ II, n = 38) and advanced stage (TNM stage III, n = 24). E) Kaplan‐Meier curve analysis of overall survival of HCC patients with high Gal1 expression (IHC staining score ≥ 6, n = 35) compared with patients with low Gal1 expression (IHC staining score < 6, n = 27). F) Western blot analysis of Gal1 protein expression in shNC and shGal1 hepa1‐6 cells. G) Images of HCC tumor (left) and tumor weight (right) in the orthotopic HCC mouse models (n = 6). H) Comparison of overall survival between shNC and shGal1 orthotopic tumor models (n = 6). I) The proliferation of shNC and shGal1 cells measured by CCK8 assay. J) Flow chart of shNC and shGal1 cell implantation and macrophage depletion. K) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC mouse models with or without macrophage depletion (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Article Snippet: Furthermore, OTX008 (50 μg ml −1 ), anti‐mouse CCL20 antibody (20 μg ml −1 , ab9829, Abcam) or recombinant Gal1 (10 μg ml −1 , 450‐39, PeproTech) was added to these cells.

Techniques: Expressing, Comparison, Immunohistochemistry, Immunohistochemical staining, Staining, Western Blot, CCK-8 Assay

TAMs are critical mediators in the establishment of immunosuppressive TME induced by Gal1. A) Analysis of the correlation between Gal1 expression and CD8 + T cell infiltration (left) and Treg infiltration (right) in TCGA database. B) Representative images (upper) of IF staining with Foxp3 (red), CD8 (green), DAPI (blue) in HCC tissues with high Gal1 expression (IHC staining score ≥ 6) and low Gal1 expression (IHC staining score < 6); (lower) quantification of Foxp3 + and CD8 + cells in HCC tissues. C) Flow cytometry analysis of CD4 + CD25 + Foxp3 + Treg infiltration in orthotopic HCC mouse models with or without macrophage depletion (n = 6). D) Flow cytometry analysis of the proportion of CD8 + T cells in orthotopic HCC mouse models (n = 6). E) Representative IHC staining images and quantification of Foxp3 + and CD8 + cells in mouse tumor tissues (n = 6). F) Flow cytometry analysis of the proportion of PD‐1 + LAG‐3 + CD8 + T cells in orthotopic HCC mouse models (n = 6). G) Percentage of IFN‐γ + , TNF‐α + , granzyme B + and perforin + CD8 + T cells assessed by flow cytometry (n = 6). H) Flow cytometry analysis of NK1.1 + cell infiltration in the orthotopic HCC mouse models (n = 6). I) The proportion of CD8 + T cells in the orthotopic HCC mouse models treated with isotype or anti‐CD8 mAb (n = 6). J) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC mouse models treated with isotype or anti‐CD8 mAb (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Journal: Advanced Science

Article Title: Galectin‐1‐Induced Tumor Associated Macrophages Repress Antitumor Immunity in Hepatocellular Carcinoma Through Recruitment of Tregs

doi: 10.1002/advs.202408788

Figure Lengend Snippet: TAMs are critical mediators in the establishment of immunosuppressive TME induced by Gal1. A) Analysis of the correlation between Gal1 expression and CD8 + T cell infiltration (left) and Treg infiltration (right) in TCGA database. B) Representative images (upper) of IF staining with Foxp3 (red), CD8 (green), DAPI (blue) in HCC tissues with high Gal1 expression (IHC staining score ≥ 6) and low Gal1 expression (IHC staining score < 6); (lower) quantification of Foxp3 + and CD8 + cells in HCC tissues. C) Flow cytometry analysis of CD4 + CD25 + Foxp3 + Treg infiltration in orthotopic HCC mouse models with or without macrophage depletion (n = 6). D) Flow cytometry analysis of the proportion of CD8 + T cells in orthotopic HCC mouse models (n = 6). E) Representative IHC staining images and quantification of Foxp3 + and CD8 + cells in mouse tumor tissues (n = 6). F) Flow cytometry analysis of the proportion of PD‐1 + LAG‐3 + CD8 + T cells in orthotopic HCC mouse models (n = 6). G) Percentage of IFN‐γ + , TNF‐α + , granzyme B + and perforin + CD8 + T cells assessed by flow cytometry (n = 6). H) Flow cytometry analysis of NK1.1 + cell infiltration in the orthotopic HCC mouse models (n = 6). I) The proportion of CD8 + T cells in the orthotopic HCC mouse models treated with isotype or anti‐CD8 mAb (n = 6). J) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC mouse models treated with isotype or anti‐CD8 mAb (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Article Snippet: Furthermore, OTX008 (50 μg ml −1 ), anti‐mouse CCL20 antibody (20 μg ml −1 , ab9829, Abcam) or recombinant Gal1 (10 μg ml −1 , 450‐39, PeproTech) was added to these cells.

Techniques: Expressing, Staining, Immunohistochemistry, Flow Cytometry

Tumor‐derived Gal1 facilitates Tregs recruitment through upregulating CCL20 expression in TAMs. A) Schematic workflow showing BMDM and tumor cell co‐culture and RNA‐sequencing. B) Volcano plot of differentially expressed genes based on RNA‐sequencing. C) Pathway enrichment analysis of RNA‐sequencing dataset. D) Cluster heatmap of differentially expressed chemokines based on RNA‐sequencing. E) Changes in chemokine levels according to RNA‐sequencing. F) qPCR analysis of CCL20 expression in BMDMs cultured with conditioned medium from shGal1 or shNC hepa1‐6 cells for 24 hours (left, n = 3); ELISA analysis of CCL20 protein expression in supernatants (right, n = 3). G) qPCR analysis of CCL20 expression in shGal1 or shNC hepa1‐6 cells (left, n = 3); ELISA analysis of CCL20 protein expression in the supernatants from shGal1 or shNC hepa1‐6 cells (right, n = 3). H) Flow cytometry analysis of CCL20 expression in TAMs in the orthotopic HCC mouse models (n = 6). I) The proportion of CCR6 + Tregs in the orthotopic HCC mouse models assessed by flow cytometry (n = 6). J) ELISA analysis of CCL20 protein level in tumor tissues from the orthotopic HCC mouse models with or without macrophage depletion (n = 6). K) Schematic diagram of Treg chemotaxis assay. L) Flow cytometry analysis of the number of migrated CD4 + CD25 + Foxp3 + Tregs (n = 3). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Journal: Advanced Science

Article Title: Galectin‐1‐Induced Tumor Associated Macrophages Repress Antitumor Immunity in Hepatocellular Carcinoma Through Recruitment of Tregs

doi: 10.1002/advs.202408788

Figure Lengend Snippet: Tumor‐derived Gal1 facilitates Tregs recruitment through upregulating CCL20 expression in TAMs. A) Schematic workflow showing BMDM and tumor cell co‐culture and RNA‐sequencing. B) Volcano plot of differentially expressed genes based on RNA‐sequencing. C) Pathway enrichment analysis of RNA‐sequencing dataset. D) Cluster heatmap of differentially expressed chemokines based on RNA‐sequencing. E) Changes in chemokine levels according to RNA‐sequencing. F) qPCR analysis of CCL20 expression in BMDMs cultured with conditioned medium from shGal1 or shNC hepa1‐6 cells for 24 hours (left, n = 3); ELISA analysis of CCL20 protein expression in supernatants (right, n = 3). G) qPCR analysis of CCL20 expression in shGal1 or shNC hepa1‐6 cells (left, n = 3); ELISA analysis of CCL20 protein expression in the supernatants from shGal1 or shNC hepa1‐6 cells (right, n = 3). H) Flow cytometry analysis of CCL20 expression in TAMs in the orthotopic HCC mouse models (n = 6). I) The proportion of CCR6 + Tregs in the orthotopic HCC mouse models assessed by flow cytometry (n = 6). J) ELISA analysis of CCL20 protein level in tumor tissues from the orthotopic HCC mouse models with or without macrophage depletion (n = 6). K) Schematic diagram of Treg chemotaxis assay. L) Flow cytometry analysis of the number of migrated CD4 + CD25 + Foxp3 + Tregs (n = 3). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Article Snippet: Furthermore, OTX008 (50 μg ml −1 ), anti‐mouse CCL20 antibody (20 μg ml −1 , ab9829, Abcam) or recombinant Gal1 (10 μg ml −1 , 450‐39, PeproTech) was added to these cells.

Techniques: Derivative Assay, Expressing, Co-Culture Assay, RNA Sequencing, Cell Culture, Enzyme-linked Immunosorbent Assay, Flow Cytometry, Chemotaxis Assay

Tregs recruited by Gal1‐induced TAMs contribute to impaired functionality of CD8 + T cells. A) Flow chart of Treg depletion in Foxp3DTR mice. B) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC mouse models with or without Treg depletion (n = 6). C) Infiltration of CD8 + T cells in the orthotopic HCC mouse models was determined by flow cytometry (n = 6). D) Flow cytometry analysis of IFN‐γ + , TNF‐α + , granzyme B + and perforin + CD8 + T cells in the orthotopic HCC models (n = 6). E) Schematic flow diagram of shNC and shGal1 cell implantation and CCL20 neutralization. F) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC models treated with isotype or anti‐CCL20 antibody (n = 6). G) Flow cytometry analysis of CD4 + CD25 + Foxp3 + Tregs in the orthotopic HCC models (n = 6). H) The proportion of CCR6 + Tregs in the orthotopic HCC models was assessed by flow cytometry (n = 6). I) Representative IHC staining images (upper) and quantification (lower) of Foxp3 + and CD8 + cells in mouse tumor tissues (n = 6). J) Flow cytometry analysis of the infiltration of CD8 + T cells in the orthotopic HCC mouse models (n = 6). K) Flow cytometry analysis of the expression of anti‐tumor cytokines (IFN‐γ, TNF‐α, granzyme B and perforin) in CD8 + T cells in the orthotopic HCC mouse models (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Journal: Advanced Science

Article Title: Galectin‐1‐Induced Tumor Associated Macrophages Repress Antitumor Immunity in Hepatocellular Carcinoma Through Recruitment of Tregs

doi: 10.1002/advs.202408788

Figure Lengend Snippet: Tregs recruited by Gal1‐induced TAMs contribute to impaired functionality of CD8 + T cells. A) Flow chart of Treg depletion in Foxp3DTR mice. B) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC mouse models with or without Treg depletion (n = 6). C) Infiltration of CD8 + T cells in the orthotopic HCC mouse models was determined by flow cytometry (n = 6). D) Flow cytometry analysis of IFN‐γ + , TNF‐α + , granzyme B + and perforin + CD8 + T cells in the orthotopic HCC models (n = 6). E) Schematic flow diagram of shNC and shGal1 cell implantation and CCL20 neutralization. F) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC models treated with isotype or anti‐CCL20 antibody (n = 6). G) Flow cytometry analysis of CD4 + CD25 + Foxp3 + Tregs in the orthotopic HCC models (n = 6). H) The proportion of CCR6 + Tregs in the orthotopic HCC models was assessed by flow cytometry (n = 6). I) Representative IHC staining images (upper) and quantification (lower) of Foxp3 + and CD8 + cells in mouse tumor tissues (n = 6). J) Flow cytometry analysis of the infiltration of CD8 + T cells in the orthotopic HCC mouse models (n = 6). K) Flow cytometry analysis of the expression of anti‐tumor cytokines (IFN‐γ, TNF‐α, granzyme B and perforin) in CD8 + T cells in the orthotopic HCC mouse models (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Article Snippet: Furthermore, OTX008 (50 μg ml −1 ), anti‐mouse CCL20 antibody (20 μg ml −1 , ab9829, Abcam) or recombinant Gal1 (10 μg ml −1 , 450‐39, PeproTech) was added to these cells.

Techniques: Flow Cytometry, Neutralization, Immunohistochemistry, Expressing

Gal1 upregulates CCL20 through activation of the PI3K/AKT/NF‐κB signaling pathway in TAMs. A) Pathway enrichment analysis of differentially expressed genes based on RNA‐sequencing. B) Protein levels of PI3K/AKT/NF‐κB pathway in BMDMs incubated in the conditioned medium for 24 hours were determined by western blot. C) Representative IF images (left) and quantification (right) of P65 nuclear translocation in BMDMs incubated in the conditioned medium (n = 3). D) ELISA analysis of CCL20 protein expression in supernatants of BMDMs cultured with conditioned medium from shGal1 or shNC hepa1‐6 cells for 24 hours (n = 3). E) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC models treated with vehicle or BAY 11–7082 (n = 6). F) CCL20 expression in TAMs in the orthotopic HCC models was measured by flow cytometry (n = 6). G) Flow cytometry analysis of the proportion of CCR6 + Tregs in the orthotopic HCC models (n = 6). H) Flow cytometry analysis of CD4 + CD25 + Foxp3 + Tregs in the orthotopic HCC models (n = 6). I) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC models treated with vehicle or LY294002 (n = 6). J) Flow cytometry analysis of CCL20 expression in TAMs in the orthotopic HCC models (n = 6). K) Flow cytometry analysis of the proportion of CCR6 + Tregs in the orthotopic HCC models (n = 6). L) Flow cytometry analysis of CD4 + CD25 + Foxp3 + Tregs in the orthotopic HCC models (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Journal: Advanced Science

Article Title: Galectin‐1‐Induced Tumor Associated Macrophages Repress Antitumor Immunity in Hepatocellular Carcinoma Through Recruitment of Tregs

doi: 10.1002/advs.202408788

Figure Lengend Snippet: Gal1 upregulates CCL20 through activation of the PI3K/AKT/NF‐κB signaling pathway in TAMs. A) Pathway enrichment analysis of differentially expressed genes based on RNA‐sequencing. B) Protein levels of PI3K/AKT/NF‐κB pathway in BMDMs incubated in the conditioned medium for 24 hours were determined by western blot. C) Representative IF images (left) and quantification (right) of P65 nuclear translocation in BMDMs incubated in the conditioned medium (n = 3). D) ELISA analysis of CCL20 protein expression in supernatants of BMDMs cultured with conditioned medium from shGal1 or shNC hepa1‐6 cells for 24 hours (n = 3). E) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC models treated with vehicle or BAY 11–7082 (n = 6). F) CCL20 expression in TAMs in the orthotopic HCC models was measured by flow cytometry (n = 6). G) Flow cytometry analysis of the proportion of CCR6 + Tregs in the orthotopic HCC models (n = 6). H) Flow cytometry analysis of CD4 + CD25 + Foxp3 + Tregs in the orthotopic HCC models (n = 6). I) Representative image of tumor (left) and tumor weight (right) in the orthotopic HCC models treated with vehicle or LY294002 (n = 6). J) Flow cytometry analysis of CCL20 expression in TAMs in the orthotopic HCC models (n = 6). K) Flow cytometry analysis of the proportion of CCR6 + Tregs in the orthotopic HCC models (n = 6). L) Flow cytometry analysis of CD4 + CD25 + Foxp3 + Tregs in the orthotopic HCC models (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Article Snippet: Furthermore, OTX008 (50 μg ml −1 ), anti‐mouse CCL20 antibody (20 μg ml −1 , ab9829, Abcam) or recombinant Gal1 (10 μg ml −1 , 450‐39, PeproTech) was added to these cells.

Techniques: Activation Assay, RNA Sequencing, Incubation, Western Blot, Translocation Assay, Enzyme-linked Immunosorbent Assay, Expressing, Cell Culture, Flow Cytometry

Blocking Gal1 reverses the anti‐PD1 resistance in HCC. A) Comparison of TIDE scores between Gal1 high expression and Gal1 low expression groups in TCGA cohort. B) Image of HCC tumors (left) and quantification of tumor weight (right) in orthotopic HCC models treated with OTX008, anti‐PD‐1 mAb or combination therapy (n = 6). C) Overall survival of tumor‐bearing mice treated with monotherapy or combination therapy (n = 6). D) Flow cytometry analysis of CCL20 expression in TAMs in the orthotopic HCC models with different treatment (n = 6). E) Flow cytometry analysis of CD4 + CD25 + Foxp3 + Tregs in the orthotopic HCC models (n = 6). F) The percentage of CCR6 + Tregs in the orthotopic HCC models was determined by flow cytometry (n = 6). G) Representative IHC staining images (upper) and quantification (lower) of Foxp3 + and CD8 + cells in the orthotopic HCC models with different treatment (n = 6). H) The number of live CD8 + T cells in the orthotopic HCC models was assessed by flow cytometry (n = 6). I) Intracellular staining of granzyme B, perforin, IFN‐γ and TNF‐α in CD8 + T cells in the orthotopic HCC models was determined by flow cytometry (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Journal: Advanced Science

Article Title: Galectin‐1‐Induced Tumor Associated Macrophages Repress Antitumor Immunity in Hepatocellular Carcinoma Through Recruitment of Tregs

doi: 10.1002/advs.202408788

Figure Lengend Snippet: Blocking Gal1 reverses the anti‐PD1 resistance in HCC. A) Comparison of TIDE scores between Gal1 high expression and Gal1 low expression groups in TCGA cohort. B) Image of HCC tumors (left) and quantification of tumor weight (right) in orthotopic HCC models treated with OTX008, anti‐PD‐1 mAb or combination therapy (n = 6). C) Overall survival of tumor‐bearing mice treated with monotherapy or combination therapy (n = 6). D) Flow cytometry analysis of CCL20 expression in TAMs in the orthotopic HCC models with different treatment (n = 6). E) Flow cytometry analysis of CD4 + CD25 + Foxp3 + Tregs in the orthotopic HCC models (n = 6). F) The percentage of CCR6 + Tregs in the orthotopic HCC models was determined by flow cytometry (n = 6). G) Representative IHC staining images (upper) and quantification (lower) of Foxp3 + and CD8 + cells in the orthotopic HCC models with different treatment (n = 6). H) The number of live CD8 + T cells in the orthotopic HCC models was assessed by flow cytometry (n = 6). I) Intracellular staining of granzyme B, perforin, IFN‐γ and TNF‐α in CD8 + T cells in the orthotopic HCC models was determined by flow cytometry (n = 6). Data were presented as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Article Snippet: Furthermore, OTX008 (50 μg ml −1 ), anti‐mouse CCL20 antibody (20 μg ml −1 , ab9829, Abcam) or recombinant Gal1 (10 μg ml −1 , 450‐39, PeproTech) was added to these cells.

Techniques: Blocking Assay, Comparison, Expressing, Flow Cytometry, Immunohistochemistry, Staining

Schematic representations of Gal1‐induced TAMs in maintaining the immunosuppressive tumor microenvironment in HCC.

Journal: Advanced Science

Article Title: Galectin‐1‐Induced Tumor Associated Macrophages Repress Antitumor Immunity in Hepatocellular Carcinoma Through Recruitment of Tregs

doi: 10.1002/advs.202408788

Figure Lengend Snippet: Schematic representations of Gal1‐induced TAMs in maintaining the immunosuppressive tumor microenvironment in HCC.

Article Snippet: Furthermore, OTX008 (50 μg ml −1 ), anti‐mouse CCL20 antibody (20 μg ml −1 , ab9829, Abcam) or recombinant Gal1 (10 μg ml −1 , 450‐39, PeproTech) was added to these cells.

Techniques:

Kinetics and thermodynamics of binding of  sLe x  and Le x conjugates to scFvs

Journal:

Article Title: Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewis x and Lewis x

doi:

Figure Lengend Snippet: Kinetics and thermodynamics of binding of sLe x and Le x conjugates to scFvs

Article Snippet: Immunotubes (Maxisorb, Nunc) were coated overnight at 4°C with 1 ml of 10 μg/ml sLe x -BSA (Oxford GlycoSystems, Bedford, MA) in PBS (10 mM phosphate/150 mM NaCl, pH 7.4) except for the last round of panning when the tube was coated with only 1 μg/ml sLe x -BSA to enrich the higher affinity phage.

Techniques: Binding Assay